Core Viewpoint - The company, 东方生物, is experiencing a slight decline in stock price and is preparing for an upcoming shareholder meeting to elect a new independent director and discuss various corporate matters [1][4]. Company Announcements - 东方生物 will hold its second extraordinary general meeting of shareholders on November 20, 2025, to vote on the election of independent director 陈军泽 and adjustments to the specialized committees [1][4]. - The meeting will utilize a combination of on-site and online voting, with the record date set for November 13, 2025 [1]. - The company has received multiple medical device registration certificates for its subsidiary, 上海万子健, including test kits for gastrin-17 and NT-proBNP, which are used for diagnosing atrophic gastritis and heart failure [2][4]. Independent Director Nomination - 陈军泽 has been nominated as a candidate for independent director, with qualifications that meet regulatory requirements, including over five years of relevant work experience and no conflicts of interest [3][4]. - The nomination committee has reviewed and approved his qualifications, and he will also serve on several specialized committees if elected [2][3].